Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Publication|Videos|October 3, 2024
Parexel’s FSP: Evolving With Your Needs Now and in the Future
Author(s)PAREXEL
Jenny Denney, EVP, Head of FSP Clinical and Biometrics at Parexel, discusses current transformations in the industry in addition to how Parexel, as the landscape shifts, supports clients with proper models and infrastructure from a functional service provider (FSP) perspective.
• A one-size-fits-all model no longer exists. Because of this, Parexel's models are flexible and agile, designed to adapt to customer needs and their shifting pipeline priorities—and whatever challenges they face.
• One of Parexel's key differentiators is its people-centric approach. The company does everything with heart. While technology plays a significant role in transforming the industry, it is ultimately powered by Parexel's dedicated people.
• Parexel has a remarkable global infrastructure that spans across numerous countries. This infrastructure allows it to provide real-time connectivity and ensures it can find the right people in the right place at the right time, which is essential for the success of the FSP model.
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5